Business Wire

NY-CLARITY-AI

15.5.2023 09:31:29 CEST | Business Wire | Press release

Share
Clarity AI: Only 4% of “Sustainable” Investment Funds Would Automatically Comply with Requirements of US, UK and EU Regulatory Investment Fund Label and Naming Rules

Clarity AI, the leading sustainability tech platform, released a new analysis on funds with sustainability or ESG-related terms in their name. The report found that regulatory regimes for sustainability disclosures and labels differ significantly across the US, UK and EU, leaving both issuers and investors confused.

“When looking at funds with all three investment fund regimes – the US’, UK’s, and EU’s – we found that over 95% of funds with the word “sustainable”, or similar term, would require renaming or restructuring in order to be sold across all three markets. This is not only an added cost in terms of compliance, but also underscores how different actors – in this case regulators – are interpreting the meaning of core concepts like ESG and sustainability.” said Patricia Pina, Head of Product Research and Innovation at Clarity AI.

When looking specifically at the EU, in November 2022 the European Securities and Markets Authority (ESMA) released a consultation that sought to put minimum thresholds in place for Article 8 – or “light green” – funds that use certain ESG or sustainability-related terms in their names. ESMA proposed that any fund using an ESG-related term in its name would need to ensure that:

  • 100% of the assets it invests in adhere to minimum safeguards by following the minimum exclusion criteria outlined in the Paris-aligned benchmark regulation.
  • 80% of the assets it invests in are used to meet the ESG-related characteristics that it promotes (i.e. aligned with the terms in the name).
  • 50% of the assets it invests in are sustainable investments as defined under Article 2(17) of SFDR, if the fund uses the term “sustainable” or any derived term (e.g. “sustain”) in its name.

Clarity AI examined these proposals, drawing on data from over 18,000 funds across Europe. To test the ESMA proposals on the funds that do have references to ESG, Clarity AI looked at the planned (via European ESG Templates, or EETs) and actual (via Clarity AI’s own data) level of sustainable investment in different Article 8 funds. Clarity AI’s analysis found only 20% of Article 8 funds with the term sustainable (or a derivative thereof) currently plan to make sustainable investment of over 50% as outlined by the consultation. These funds would therefore fall short of the proposed amendments. In fact, the picture is bleak in terms of sustainable investment made by Article 8 funds with “sustainable” in their names: a similar number (20%) plan to make less than 10% sustainable investment. Furthermore, the proposal from ESMA does not appear to align particularly closely with either of the proposals from the UK or the US.

"Although each jurisdiction might have contextual differences worth taking into account, capital markets are global markets and we need stronger regulatory alignment across borders. Understanding and characterizing ESG and sustainability differently will only contribute to increasing the existing confusion in the market and potentially result in ‘greenwashing,’ which is exactly what these regulations aim to fight, " added Pina.

To promote transparency, Clarity AI addresses the confusion by providing an unbiased view of portfolio sustainability, mapping frameworks and regulatory labels across jurisdictions. However, understanding the challenges and pitfalls of cross-border regulations is essential to combat limited regulatory alignment. Advanced technology can help ensure that investors remain safe and result in better outcomes for investors, markets, and the transition to a sustainable economy.

About Clarity AI

Clarity AI is a sustainability technology platform that uses machine learning and big data to deliver environmental and social insights to investors, organizations, and consumers. Clarity AI’s capabilities are an essential tool for end-to-end sustainability analysis related to investing, corporate research, benchmarking, consumer ecommerce, and regulatory reporting. As of May 2023, Clarity AI’s platform analyzes more than 70,000 companies, 390,000 funds, 198 countries, and 199 local governments, which represents more breadth than any other player in the market. One way Clarity AI delivers on its mission to bring societal impact to markets is by ensuring its capabilities are delivered directly into clients' workflows through integrations with partners like BlackRock - Aladdin, Refinitiv an LSEG business, BNP Manaos, CACEIS, and Simcorp. Additionally, Clarity AI's sustainability insights reach more than 150 million consumers across more than 400,000 merchants on the Klarna platform. Clarity AI has offices in North America, Europe, and the Middle East, and its client network manages tens of trillions in assets and includes companies like Invesco, Nordea, BlackRock, Santander, Wellington, and BNP Paribas.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230515005230/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vonage Expands Developer Ecosystem to Accelerate the Next Era of Enterprise Digital Transformation19.2.2026 10:08:00 CET | Press release

Vonage verified Postman workspace extends reach by 40+ million developers; MCP servers and Startup Program among resources designed to further accelerate time-to-value for developers and enterprises Vonage, part of Ericsson (NASDAQ: ERIC), today announced a number of new initiatives, to further expand and enable its global developer community. By growing its developer community and tools, giving developers and enterprises access to new mobile network insights and capabilities that can be embedded into existing applications and workflows, Vonage is accelerating its strategy to transform mobile networks into a programmable platform. Putting Vonage APIs in the Hands of 40 million+ More Developers Vonage is announcing the launch of its Verified Workspace on the Postman API Network, making Vonage APIs available to the 40+ million developers who use Postman. The new, verified workspace gives Postman’s community of global developer members certified access to Vonage’s portfolio of Network API

Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 202619.2.2026 08:50:00 CET | Press release

Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American Association for Cancer Research Immuno-Oncology (AACRIO) annual conference (February 18-21, 2026), in Los Angeles. The poster showcases new preclinical data and early clinical insights from the company's lead candidate, STC-1010, supporting it as a promising therapeutic option for MSS, immune-cold colorectal cancer (CRC)—a major unmet clinical need. In a syngeneic CT26 model, murine STC-1010 significantly inhibits tumor growth and extends survival by 40%. New mechanistic datas reveal expansion of CD4⁺ and CD8⁺ T cells in draining lymph nodes alongside a significant humoral response compared to control, demonstrating coordinated cellular and humoral immune activation in vivo. Other findings show that dendritic cells efficiently capture STC-1010, leading to their activation as demonstrated by transcripto

ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer19.2.2026 08:30:00 CET | Press release

Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1 If approved, Daiichi Sankyo and AstraZeneca’s ENHERTU has the potential to become a new standard of care in this early breast cancer setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committ

NHOA Energy Advances Delivery of the 51 MWh Broni Battery for Neoen in Italy19.2.2026 08:00:00 CET | Press release

The project confirms NHOA Energy’s long-term commitment to the Italian market NHOA Energy, global provider of utility-scale energy storage systems, is advancing the construction of the Broni Battery, a 10 MW/51 MWh project located in Broni (Pavia), Italy, executed for Neoen, one of the world’s leading independent producers of renewable energy. Civil works at the site are currently underway and advancing on schedule, with commissioning activities planned to start in late spring 2026. Once operational, the Broni Battery will provide essential flexibility services to the Italian electricity system, supporting grid stability and reliability as renewable energy penetration continues to increase. The project represents Neoen’s first battery storage asset in Italy and marks a strategic step in the company’s expansion, as it continues to grow its battery storage portfolio in key markets worldwide to support power system flexibility. The Broni Battery further strengthens NHOA Energy’s long-term

Compass Pathways Announces Pricing of $150 Million Public Offering19.2.2026 02:18:00 CET | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999 per pre-funded warrant. In addition, Compass Pathways has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 ADSs at the public offering price, less the underwriting discounts and commissions. All of the securities are to be sold by Compass Pathways. The offering is expected to close on or about February 20, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Compass Pathways from the offering, before deducting underwriting discounts and commissions and other est

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye